These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 34430450)

  • 1. The Use of Apremilast in Psoriasis: An Indian Perspective on Real-World Scenarios.
    Rajagopalan M; Dogra S; Saraswat A; Varma S; Banodkar P
    Psoriasis (Auckl); 2021; 11():109-122. PubMed ID: 34430450
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Use of Apremilast in Psoriasis: A Delphi Study.
    Carrascosa JM; Belinchón I; Rivera R; Ara M; Bustinduy M; Herranz P
    Actas Dermosifiliogr (Engl Ed); 2020 Mar; 111(2):115-134. PubMed ID: 31864537
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-World Insight on Apremilast Therapy in Patients with Plaque Psoriasis: Indian Experience.
    De A; Das S; Dhoot D; Sarda A
    Indian J Dermatol; 2020; 65(5):396-400. PubMed ID: 33165422
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Needs of Patients with Psoriasis and Benefits of Apremilast in French Clinical Practice: Results from the Observational REALIZE Study.
    Jullien D; Richard MA; Halioua B; Bessette C; Derancourt C; Bouloc A
    Dermatol Ther (Heidelb); 2023 Jun; 13(6):1361-1376. PubMed ID: 37204608
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-world use of apremilast for patients with psoriasis in Japan.
    Kishimoto M; Komine M; Hioki T; Kamiya K; Sugai J; Ohtsuki M
    J Dermatol; 2018 Nov; 45(11):1345-1348. PubMed ID: 30168880
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Apremilast: A Novel Oral Treatment for Psoriasis and Psoriatic Arthritis.
    Torres T; Puig L
    Am J Clin Dermatol; 2018 Feb; 19(1):23-32. PubMed ID: 28597182
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with difficult-to-treat nail and scalp psoriasis: Results of 2 phase III randomized, controlled trials (ESTEEM 1 and ESTEEM 2).
    Rich P; Gooderham M; Bachelez H; Goncalves J; Day RM; Chen R; Crowley J
    J Am Acad Dermatol; 2016 Jan; 74(1):134-42. PubMed ID: 26549249
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Apremilast in the Treatment of Plaque Psoriasis: Differential Use in Psoriasis.
    Gao JC; Wu AG; Contento MN; Maher JM; Cline A
    Clin Cosmet Investig Dermatol; 2022; 15():395-402. PubMed ID: 35300435
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of Apremilast in Combination With Other Therapies for Treatment of Chronic Plaque Psoriasis: A Retrospective Study.
    AbuHilal M; Walsh S; Shear N
    J Cutan Med Surg; 2016 Jul; 20(4):313-6. PubMed ID: 26848145
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Apremilast: A Review in Psoriasis and Psoriatic Arthritis.
    Keating GM
    Drugs; 2017 Mar; 77(4):459-472. PubMed ID: 28213862
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-world data on the efficacy and safety of apremilast in patients with moderate-to-severe plaque psoriasis.
    Papadavid E; Rompoti N; Theodoropoulos K; Kokkalis G; Rigopoulos D
    J Eur Acad Dermatol Venereol; 2018 Jul; 32(7):1173-1179. PubMed ID: 29388335
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Apremilast, an oral phosphodiesterase-4 inhibitor, in the treatment of palmoplantar psoriasis: Results of a pooled analysis from phase II PSOR-005 and phase III Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis (ESTEEM) clinical trials in patients with moderate to severe psoriasis.
    Bissonnette R; Pariser DM; Wasel NR; Goncalves J; Day RM; Chen R; Sebastian M
    J Am Acad Dermatol; 2016 Jul; 75(1):99-105. PubMed ID: 27021239
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-World Clinical Experience With Apremilast in a Large US Retrospective Cohort Study of Patients With Moderate to Severe Plaque Psoriasis.
    Armstrong A; Levi E
    J Drugs Dermatol; 2017 Dec; 16(12):1240-1245. PubMed ID: 29240859
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and Safety of Apremilast Monotherapy for Moderate to Severe Psoriasis: Retrospective Study.
    Ighani A; Georgakopoulos JR; Zhou LL; Walsh S; Shear N; Yeung J
    J Cutan Med Surg; 2018; 22(3):290-296. PubMed ID: 29373924
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comorbidities burden and previous exposure to biological agents may predict drug survival of apremilast for psoriasis in a real-world setting.
    Kapniari E; Dalamaga M; Papadavid E
    Dermatol Ther; 2020 Nov; 33(6):e14168. PubMed ID: 32779293
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and efficacy of apremilast through 104 weeks in patients with moderate to severe psoriasis who continued on apremilast or switched from etanercept treatment: findings from the LIBERATE study.
    Reich K; Gooderham M; Bewley A; Green L; Soung J; Petric R; Marcsisin J; Cirulli J; Chen R; Piguet V
    J Eur Acad Dermatol Venereol; 2018 Mar; 32(3):397-402. PubMed ID: 29220542
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characteristics of Patients with Psoriasis Treated with Apremilast in the Corrona Psoriasis Registry.
    Gottlieb AB; Merola JF; Cirulli J; Williams CC; Linowski GJ; Paris M; Litman HJ; Guo N; Emeanuru K; McLean RR; Cronin A; Strober B
    Dermatol Ther (Heidelb); 2021 Feb; 11(1):253-263. PubMed ID: 33475970
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Apremilast: A Review in Psoriasis and Psoriatic Arthritis.
    Deeks ED
    Drugs; 2015 Aug; 75(12):1393-403. PubMed ID: 26220911
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness and safety of apremilast in biologic-naïve patients with moderate psoriasis treated in routine clinical practice in Greece: the APRAISAL study.
    Ioannides D; Antonakopoulos N; Georgiou S; Chasapi V; Katsantonis I; Drosos A; Rigopoulos D; Antoniou C; Anastasiadis G; Bassukas I; Ioannidou D; Protopapa A; Neofotistou O; Krasagakis K; Aronis P; Papageorgiou M; Lazaridou E; Patsatsi A; Lefaki I; Roussaki-Schulze AV; Satra F; Anagnostopoulos Z; Papakonstantis M
    J Eur Acad Dermatol Venereol; 2021 Sep; 35(9):1838-1848. PubMed ID: 34036627
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination Therapy of Apremilast and Biologic Agent as a Safe Option of Psoriatic Arthritis and Psoriasis.
    Metyas S; Tomassian C; Messiah R; Gettas T; Chen C; Quismorio A
    Curr Rheumatol Rev; 2019; 15(3):234-237. PubMed ID: 30499418
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.